Renlu Han

Dr. Renlu Han


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2024 in Advanced Science
Verified
Journal Article
Open access
XWXiangjun Wei
Xiangjun Wei
RHRenlu Han
Renlu Han
YGYun Gao
Yun Gao
PSPengxin Song
Pengxin Song
ZGZhen Guo
Zhen Guo
KTKeqi Tang
Keqi Tang
Bioenergetic therapy is emerging as a promising therapeutic approach. However, its therapeutic effectiveness is restricted by metabolic plasticity, as tumor cells switch metabolic phenotypes between glycolysis and oxidative phosphorylation (OXPHOS) to compensate for energy. Herein, Metformin (MET) and BAY‐876 (BAY) co‐loaded CuFe 2 O 4 (CF) nanoplatform (CFMB) is developed to boost energy deprivation by synchronous interventions of glycolysis and OXPHOS for bioenergetic therapy synergetic with chemodynamic/photothermal therapy (CDT/PTT). The MET can simultaneously restrain glycolysis and OXPHOS by inhibiting hexokinase 2 (HK2) activity and damaging mitochondrial function to deprive energy, respectively. Besides, BAY blocks glucose uptake by inhibiting glucose transporter 1 (GLUT1) expression, further potentiating the glycolysis repression and thus achieving much more depletion of tumorigenic energy sources. Interestingly, the upregulated antioxidant glutathione (GSH) in cancer cells triggers CFMB degradation to release Cu + /Fe 2+ catalyzing tumor‐overexpressed H 2 O 2 to hydroxyl radical (∙OH), both impairing OXPHOS and achieving GSH‐depletion amplified CDT. Furthermore, upon near‐infrared (NIR) light irradiation, CFMB has a photothermal conversion capacity to kill cancer cells for PTT and improve ∙OH production for enhanced CDT. In vivo experiments have manifested that CFMB remarkably suppressed tumor growth in mice without systemic toxicity. This study provides a new therapeutic modality paradigm to boost bioenergetic‐related therapies.

28 August 2022 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
HZHuijun Zhang
Huijun Zhang
RHRenlu Han
Renlu Han
PSPengxin Song
Pengxin Song
XWXiangjun Wei
Xiangjun Wei
YHYafei Hou
Yafei Hou
KTKeqi Tang
Keqi Tang

14 November 2019 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
RHRenlu Han
Renlu Han
KTKeqi Tang
Keqi Tang
YHYafei Hou
Yafei Hou
JYJiancheng Yu
Jiancheng Yu
CWChenlu Wang
Chenlu Wang
YWYou Wang
You Wang
An ultralow-intensity 808 nm NIR light with 0.25 W cm −2 synchronously activated collaborative Chemo/Photothermal/Photodynamic therapy system was developed.

1 December 2021 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
YYYuyan Yan
Yuyan Yan
YHYafei Hou
Yafei Hou
HZHuijun Zhang
Huijun Zhang
WGWenqing Gao
Wenqing Gao
RHRenlu Han
Renlu Han
KTKeqi Tang
Keqi Tang

31 October 2022 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
YYYuyan Yan
Yuyan Yan
RHRenlu Han
Renlu Han
HZHuijun Zhang
Huijun Zhang
PSPengxin Song
Pengxin Song
XWXiangjun Wei
Xiangjun Wei
KTKeqi Tang
Keqi Tang

2 February 2024 in Chemical Engineering Journal
Verified
Journal Article
Closed access
PSPengxin Song
Pengxin Song
RHRenlu Han
Renlu Han
YGYun Gao
Yun Gao
ZGZhen Guo
Zhen Guo
XWXiangjun Wei
Xiangjun Wei
KTKeqi Tang
Keqi Tang